Stem cell therapy for hereditary breast cancer.
Both hereditary and sporadic breast cancers may develop through dysregulation of self-renewal pathways of normal mammary stem cells. Networks of proto-oncogenes and tumor suppressors that control cancer cell proliferation also regulate stem cell self-renewal and possibly stem cell aging. Breast cancer susceptibility gene (BRCA1) is a nuclear phosphoprotein expressed in many nuclear processes, including stem cell regulator, DNA damage repair, recombination, transcription, ubiquitination, cell cycle checkpoint enforcement, and centrosome regulation. In this study, we report on recent advances on the functions of embryonic, fetal, and adult stem cell progenitors for hereditary breast cancer therapies. Several molecular targeting therapies are described by activation and blocking distinct developmental signaling cascade elements, such as BRCA1, EGFR, hedgehog, Wnt/beta-catenin, and/or Notch pathways, which are frequently upregulated in cancer progenitor cells during the initiation and development of breast cancer.
Rassi
H
H
National Medical Academy of Post-graduate Education Named after P.L. Shupik Health ministry of Ukraine. rasihussein@yahoo.com
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D002454:Cell Differentiation; D003131:Combined Modality Therapy; D053595:Embryonic Stem Cells / Q000166:cytology / Q000637:transplantation; D047628:Estrogen Receptor alpha / Q000235:genetics; D005260:Female; D006801:Humans; D039904:Pluripotent Stem Cells / Q000166:cytology / Q000637:transplantation; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D047628:Estrogen Receptor alpha